Update on cenobamate: long-term and subgroup analyses

Cenobamate is an investigational antiepileptic drug with a unique dual mechanism of action: it acts via the reduction of persistent…

Date: 7th October 2022

Novel targets for therapeutic intervention in movement disorders

The development of disease-modifying therapies and the identification of novel actionable targets are at the forefront of research in movement…

Date: 30th September 2022

Update on cenobamate: long-term and subgroup analyses

Cenobamate is an investigational antiepileptic drug with a unique dual mechanism of action: it acts via the reduction of persistent…

Date: 7th October 2022

Novel targets for therapeutic intervention in movement disorders

The development of disease-modifying therapies and the identification of novel actionable targets are at the forefront of research in movement…

Date: 30th September 2022

Improving ALS management: diagnosis and treatment

Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease with highly variable clinical features and prognosis, making the diagnosis challenging. And…

Date: 9th September 2022

Broadening the use of thrombectomy in stroke management

For acute ischemic stroke with large vessel occlusion, endovascular thrombectomy (EVT) has emerged as the gold standard of care, yet…

Date: 2nd September 2022

Complement inhibitors and FcRn antagonists for myasthenia gravis

Despite existing symptomatic, immunomodulatory, and immunosuppressive therapies, significant unmet needs in myasthenia gravis (MG) treatment remain. Advances in drug development…

Date: 19th August 2022

Novel imaging biomarkers in MS diagnosis and prognostication

Magnetic resonance imaging (MRI) has emerged as a powerful, noninvasive tool for diagnosis, prognostication, and treatment monitoring in multiple sclerosis…

Date: 18th August 2022

Latest guidance on pregnancy and breastfeeding in epilepsy

Women with epilepsy who are pregnant or planning to be pregnant need additional guidance and care due to the complications…

Date: 28th July 2022

Managing migraine: gepants for acute and preventive treatment

Migraine is a debilitating disease with high clinical and social impacts. The calcitonin-gene-related peptide (CGRP) pathway has shown its importance…

Date: 20th July 2022

Latest developments in the treatment of motor fluctuations in Parkinson’s disease

Parkinson’s disease (PD) is the second most common neurodegenerative disorder in the world. This high prevalence of PD has put…

Date: 8th July 2022

Accelerating time to treatment: new approaches to pre-hospital and in-hospital stroke care

Stroke is a highly time-sensitive clinical event and as such, optimizing workflow is of critical importance, even before a patient…

Date: 1st June 2022

Updates in isolated RBD

Isolated RBD (iRBD) has been established as REM sleep behavior disorder without an associated neurodegenerative condition. However, RBD is commonly…

Date: 11th May 2022

Insight into the pathogenesis of pediatric-onset MOGAD

Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) is an inflammatory disorder mainly affecting the optic nerve, spinal cord, and brain. This…

Date: 11th May 2022

Optimizing clinical trial design for improved outcomes in multiple sclerosis

Measuring the efficacy of treatments for multiple sclerosis (MS) is challenging, due to the heterogeneity of disease presentation and the…

Date: 19th April 2022

Clinical trials in neuromuscular disorders: ALS, MG & SMA

Over the past few years, a number of novel treatments for neuromuscular disorders were approved and are now available to…

Date: 21st February 2022

Subtyping in Parkinson’s disease

It is well recognized that Parkinson’s disease (PD) can present with a broad spectrum of motor and non-motor symptoms, and…

Date: 2nd February 2022

Advances in stroke rehabilitation and recovery

Stroke is a leading cause of disability worldwide. Despite considerable improvements in acute stroke treatment, most patients are left with…

Date: 2nd February 2022